Advertisement

AstraZeneca faces major setback over cancer drugs

Share This Page
 
AstraZeneca's growth plans, pinned on the promise of two novel cancer drugs, are questionable after an important clinical trial failed to demonstrate their superiority over usual care.

AstraZeneca's growth plans, pinned on the promise of two novel cancer drugs, are questionable after an important clinical trial failed to demonstrate their superiority over usual care. In the so-called Mystic study, combination therapy with the new medications was no more effective than standard chemotherapy in shrinking tumors in advanced lung cancer patients. The research results could challenge the drug maker's efforts to achieve revenue targets and compete with market leaders Merck and Bristol-Myers Squibb Co. Although the preliminary findings dealt a blow to AstraZeneca's plans, company researchers are holding on to hope that the new drug combination still might prolong overall survival in oncology patients even without shrinking their tumors.

Ad Position: 
Bottom Center Aligned
https://www.wsj.com/articles/astrazeneca-faces-major-setback-over-cancer-drugs-1501140320

Advertisement

Related Content

block-views-related-content-block